ARQT
ARQT clinical trials: Arcutis Biotherapeutics, Inc.
Every trial on ClinicalTrials.gov where Arcutis Biotherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 30
- Trials linked
- 26
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARQT on the catalyst calendar · ARQT registry changes
- Primary completion Dec 4, 2025ActualPhase 2NCT06998056Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisArcutis Biotherapeutics, Inc. · Atopic Dermatitis (Eczema)CompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2028Sponsor estimatePhase 3NCT07916480Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisArcutis Biotherapeutics, Inc. · Atopic DermatitisRecruitingARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 1NCT07453602Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234Arcutis Biotherapeutics, Inc. · Atopic Dermatitis (AD)RecruitingARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2024ActualPhase 3NCT04286607Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisArcutis Biotherapeutics, Inc. · Chronic Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2022ActualPhase 2NCT04746911Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Arcutis Biotherapeutics, Inc. · PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2026ActualPhase 1NCT07340216Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisArcutis Biotherapeutics, Inc. · PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2023ActualPhase 3NCT04845620Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)Arcutis Biotherapeutics, Inc. · Atopic Dermatitis EczemaCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2024ActualPhase 3NCT04804605Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisArcutis Biotherapeutics, Inc. · Atopic Dermatitis EczemaCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 3, 2022ActualPhase 3NCT05028582Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)Arcutis Biotherapeutics, Inc. · Scalp PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2022ActualPhase 3NCT04773600Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)Arcutis Biotherapeutics, Inc. · Atopic Dermatitis EczemaCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2022ActualPhase 3NCT04773587Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisArcutis Biotherapeutics, Inc. · Atopic Dermatitis EczemaCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 9, 2021ActualPhase 2NCT04811131Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoArcutis Biotherapeutics, Inc. · VitiligoTerminatedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2022ActualPhase 2NCT04445987Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisArcutis Biotherapeutics, Inc. · Seborrheic DermatitisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2021ActualPhase 1/Phase 2NCT04378569Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand EczemaArcutis Biotherapeutics, Inc. · Chronic Hand EczemaCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2022ActualPhase 3NCT04973228Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)Arcutis Biotherapeutics, Inc. · Seborrheic DermatitisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2022ActualPhase 2NCT04655313Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)Arcutis Biotherapeutics, Inc. · PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2, 2023ActualPhase 1NCT04156191Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate EczemaArcutis Biotherapeutics, Inc. · Atopic Dermatitis (Eczema)CompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2020ActualPhase 2NCT04091646Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisArcutis Biotherapeutics, Inc. · Seborrheic DermatitisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2019ActualPhase 2NCT03916081Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic DermatitisArcutis Biotherapeutics, Inc. · Atopic DermatitisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2020ActualPhase 3NCT04211389Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisArcutis Biotherapeutics, Inc. · Chronic Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2020ActualPhase 3NCT04211363Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisArcutis Biotherapeutics, Inc. · Chronic Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 23, 2020ActualPhase 2NCT04128007Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body PsoriasisArcutis Biotherapeutics, Inc. · Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2020ActualPhase 2NCT03764475Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque PsoriasisArcutis Biotherapeutics, Inc. · Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2019ActualPhase 2NCT03638258The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisArcutis Biotherapeutics, Inc. · Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2021ActualPhase 1NCT04279119Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque PsoriasisArcutis Biotherapeutics, Inc. · Plaque PsoriasisCompletedARQTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 5 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner